Induction of Th1-biased cytokine production by α-carba-GalCer, a neoglycolipid ligand for NKT cells

International Immunology

Volumn 22, Issue 4, 2010, Pages 319-328

  Tashiro, Takuya ^a   Sekine Kondo, Etsuko ^a   Shigeura, Tomokuni ^a   Nakagawa, Ryusuke ^a   Inoue, Sayo ^a   Omori Miyake, Miyuki ^a   Chiba, Tomoki ^a   Hongo, Naomi ^a   Fujii, Shin Ichiro ^a   Shimizu, Kanako ^a   Yoshiga, Yohei ^b   Sumida, Takayuki ^b   Mori, Kenji ^a   Watarai, Hiroshi ^a   Taniguchi, Masaru ^a  

^a RIKEN Center for Integrative Medical Sciences   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

CD1d; Glycolipid; IFN ; NKT cells; TCR

Indexed keywords

ACETAL; ALPHA GALACTOSYLCERAMIDE; CERAMIDE; CYTOKINE; GAMMA INTERFERON; GLYCOLIPID; INTERLEUKIN 12; NATURAL KILLER CELL RECEPTOR; OXYGEN; SPHINGOSINE; CYCLOHEXANOL DERIVATIVE; GALACTOSYLCERAMIDE; IMMUNOLOGICAL ADJUVANT; LIGAND;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL STIMULATION; CHEMICAL BOND; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEGRADATION KINETICS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VIVO STUDY; INFECTION RESISTANCE; LIVER MICROSOME; MOUSE; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RECEPTOR BINDING; SPLEEN CELL; TH1 CELL; TH2 CELL; TUMOR IMMUNOLOGY; ANIMAL; BIOSYNTHESIS; CELL LINE; CHEMISTRY; DRUG EFFECT; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; NATURAL KILLER T CELL; SYNTHESIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELL LINE; CYCLOHEXANOLS; CYTOKINES; GALACTOSYLCERAMIDES; GLYCOLIPIDS; HUMANS; INJECTIONS, INTRAVENOUS; LIGANDS; MICE; NATURAL KILLER T-CELLS; TH1 CELLS;

EID: 77954045916     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxq012     Document Type: Article

References (29)

1. Taniguchi, M., Harada, M., Kojo, S., Nakayama, T. and Wakao, H. 2003. The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu. Rev. Immunol. 21:483.
2. Wilson, S. B. and Delovitch, T. L. 2003. Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity. Nat. Rev. Immunol. 3:211.
3. Brigl, M., Bry, L., Kent, S. C., Gumperz, J. E. and Brenner, M. B. 2003. Mechanism of CD1d restricted natural killer T cell activation during microbial infection. Nat. Immunol. 4:1230.
4. Cui, J., Shin, T., Kawano, T. et al. 1997. Requirement for Va14 NKT cells in IL-12-mediated rejection of tumors. Science 278:1623.
5. Fujii, S., Shimizu, K., Smith, C., Bonifaz, L. and Steinman, R. M. 2003. Activation of natural killer Tcells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J. Exp. Med. 198:267.
6. Dhodapkar, M. V. 2009. Harnessing human CD1d restricted T cells for tumor immunity: progress and challenges. Front. Biosci. 14:796.
7. Cerundolo, V. and Salio, M. 2007. Harnessing NKT cells for therapeutic applications. Curr. Top. Microbiol. Immunol. 314:325.
8. Wu, L. and Van Kaer, L. 2009. Natural killer T cells and autoimmune disease. Curr. Mol. Med. 9:4.
9. Koch, M., Stronge, V. S., Shepherd, D. et al. 2005. The crystal structure of human CD1d with and without alpha-galactosylceramide. Nat. Immunol. 6:819.
10. Zeng, Z., Castaño, A. R., Segelke, B. W., Stura, E. A., Peterson, P. A. and Wilson, I. A. 1997. Crystal structure of mouse CD1: an MHC-like fold with a large hydrophobic binding groove. Science 277:339.
11. Kawano, T., Cui, J., Koezuka, Y. et al. 1997. CD1d-restricted and TCR-mediated activation of Va14 NKT cells by glycosylceramides. Science 278:626.
12. McCarthy, C., Shepherd, D., Fleire, S. et al. 2007. The length of lipids bound to human CD1d molecules modulates the affinity of NKTcell TCR and the threshold of NKTcell activation. J. Exp. Med. 204:1131.
13. Oki, S., Chiba, A., Yamamura, T. and Miyake, S. 2004. The clinical implication and molecular mechanism of preferential IL-4 pro- duction by modified glycolipid-stimulated NKT cells. J. Clin. Invest. 113:1631.
14. Oki, S., Tomi, C., Yamamura, T. and Miyake, S. 2005. Preferential T(h)2 polarization by OCH is supported by incompetent NKT cell induction of CD40L and following production of inflammatory cytokines by bystander cells in vivo. Int. Immunol. 17:1619.
15. Tashiro, T., Nakagawa, R., Inoue, S. et al. 2007. RCAI-56, a carbocyclic analogue of KRN7000: its synthesis and potent activity for natural killer (NK) T cells to preferentially produce interferon-γ. Tetrahedron Lett. 48:3343.
16. Watarai, H., Nakagawa, R., Omori-Miyake, M., Dashtsoodol, N. and Taniguchi, M. 2008. Methods for detection, isolation and culture of mouse and human invariant NKT cells. Nat. Protoc. 3:70.
17. Yanagihara, S., Komura, E., Nagafune, J., Watarai, H. and Yamaguchi, Y. 1998. EBI1/CCR7 is a new member of dendritic cell chemokine receptor that is up-regulated upon maturation. J. Immunol. 161:3096.
18. Willcox, B. E., Gao, G. F., Wyer, J. R. et al. 1999. TCR binding to peptide-MHC stabilizes a flexible recognition interface. Immunity 10:357.
19. Zajonc, D. M., Cantu, C. 3rd, Mattner, J. et al. 2005. Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor. Nat. Immunol. 6:810.
20. Schmieg, J., Yang, G., Franck, R. W. and Tsuji, M. 2003. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand a-galactosylceramide. J. Exp. Med. 198:1631.
21. Naidenko, O. V., Maher, J. K., Ernst, W. A., Sakai, T., Modlin, R. L. and Kronenberg, M. 1999. Binding and antigen presentation of ceramide-containing glycolipids by soluble mouse and human CD1d molecules. J. Exp. Med. 190:1069.
22. Liu, Y., Goff, R. D., Zhou, D. et al. 2006. A modified α-galactosyl ceramide for staining and stimulating natural killer T cells. J. Immunol. Methods 312:34.
23. Greten, T. F., Korangy, F., Neumann, G. et al. 2002. Peptide-beta2-microglobulin-MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC-Ig complexes. J. Immunol. Methods 271:125.
24. Hayakawa, Y., Takeda, K., Yagita, H., Van Kaer, L., Saiki, I. and Okumura, K. 2001. Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways. J. Immunol. 166:6012.
25. Sidobre, S., Naidenko, O. V., Sim, B. C., Gascoigne, N. R., Garcia, K. C. and Kronenberg, M. 2002. The V alpha 14 NKT cell TCR exhibits high-affinity binding to a glycolipid/CD1d complex. J. Immunol. 169:1340.
26. Houston, J. B. and Galetin, A. 2008. Methods for predicting in vivo pharmacokinetics using data from in vitro assays. Curr. Drug Metab. 9:940.
27. Li, X., Chen, G., Garcia-Navarro, R., Franck, R. W. and Tsuji, M. 2009. Identification of C-glycoside analogues that display a potent biological activity against murine and human invariant natural killer T cells. Immunology 127:216.
28. Lee, P. T., Benlagha, K., Teyton, L. and Bendelac, A. 2002. Distinct functional lineages of human V(alpha)24 natural killer T cells. J. Exp. Med. 195:637.
29. Borg, N. A., Wun, K. S., Kjer-Nielsen, L. et al. 2007. CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature 448:44.